Caballero, Teresa
Ferrer, Marta
Guilarte, Mar
Funding for this research was provided by:
Novartis Pharmaceuticals
Universidad de Navarra
Article History
Accepted: 3 October 2022
First Online: 30 October 2022
Declarations
:
: All authors equally participated in the development of the Delphi study and the manuscript, had full editorial control, reviewed and edited various drafts, and provided their final approval of all content and submission for publication.
: Novartis Pharmaceuticals provided economic funding for this work. The sponsor had no role in the design, analysis and interpretation of the data, the wording of the article, or the decision to send the article for publication.
: Teresa Caballero is/has been a member of advisory boards for BioCryst, CSL Behring, Novartis, Octapharma, Pharming, and Takeda; is/has been a member of speakers’ bureaus for CSL Behring, Novartis, Pharming, and Takeda; has received grants or honoraria from BioCryst, CSL Behring, Novartis, and Takeda; has received funding to attend conferences/educational events from CSL Behring, Novartis, and Takeda; is/has been a clinical trial/registry investigator for BioCryst, CSL Behring, Novartis, Pharming, and Takeda; and is a researcher from the IdiPAZ program for promoting research activities. Marta Ferrer has been a speaker, advisory board member, and/or investigator for Genentech, Novartis, Sanofi, Menarini, Uriach, FAES, and MSD; and has received grants from GSK and Novartis. Mar Guilarte has received honoraria for educational purposes from CSL Behring, Novartis, and Takeda; has participated in advisory boards organized by CSL Behring, Novartis, and Takeda; has received funding to attend conferences and educational events from CSL Behring, Novartis, Pharming, and Takeda; and is a clinical trial/registry investigator for BioCryst, CSL Behring, Novartis, Pharming, Pharvaris, and Takeda, and a researcher from the VHIR program for promoting research activities.
: Not applicable.
: Not applicable.
: Not applicable.